VYEPTI (Lundbeck Australia Pty Ltd)
Product name
VYEPTI
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
213 (255 working days)
Active ingredients
eptinezumab
Registration type
NCE/NBE
Indication
VYEPTI (concentrated injection for dilution for infusion) is indicated for the preventive treatment of migraine in adults.